Cue Biopharma Announces Presentation at the Society for Immunotherapy of Cancer’s (SITC) 33rd Annual Meeting
Cue Biopharma, Inc. (CUE)
US:NASDAQ Investor Relations:
cuebiopharma.gcs-web.com/news-releases
Company Research
Source: GlobeNewswire
CAMBRIDGE, Mass., Oct. 30, 2018 (GLOBE NEWSWIRE) -- Cue Biopharma™, Inc., (NASDAQ: CUE) an innovative immunotherapy company developing a novel, proprietary class of biologics engineered to selectively modulate the human immune system to treat cancer, autoimmune and chronic infectious diseases, announced today a poster presentation on its lead candidate CUE-101, an Immuno-STAT™ (Selective Targeting and Alteration of T cells) Biologic being developed for the treatment of HPV-associated cancers, at the Society for Immunotherapy of Cancer's (SITC) 33rd Annual Meeting being held November 7-11, 2018, in Washington, D.C. Title: CUE-101, a novel Fc fusion protein comprised of HLA-A*0201-bound HPV16 E7 peptide and IL-2, for selective targeting and expansion of anti-tumor T cells for treatment of HPV-driven malignancies Poster Number: P185Location: Hall E, Walter E. Washington Convention CenterAuthors: Steven N. Quayle, Dharma Raj Thapa, Sandrine Hulot, Alyssa Nelson, Lauren Kraemer, Zohra
Show less
Read more
Impact Snapshot
Event Time:
CUE
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CUE alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CUE alerts
High impacting Cue Biopharma, Inc. news events
Weekly update
A roundup of the hottest topics
CUE
News
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire
- Here's Why Cue Biopharma (CUE) Is a Great 'Buy the Bottom' Stock Now [Yahoo! Finance]Yahoo! Finance
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "buy" rating re-affirmed by analysts at Stifel Nicolaus. They now have a $8.00 price target on the stock.MarketBeat
- Cue Biopharma, Inc. (NASDAQ: CUE) had its "outperform" rating re-affirmed by analysts at Oppenheimer Holdings Inc.. They now have a $10.00 price target on the stock.MarketBeat
CUE
Earnings
- 8/8/23 - Beat
CUE
Sec Filings
- 3/28/24 - Form 10-K
- 3/28/24 - Form S-8
- 3/11/24 - Form SC
- CUE's page on the SEC website